ReviewFrontiers in immunology2020
Diagnosis for Latent Tuberculosis Infection: New Alternatives.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 8 syntheses or guidelines pooled it, 202 citations in OpenAlex.
- Association between latent tuberculosis infection and assisted reproductive outcomes: a systematic review and meta-analysis.BMJ open · 2025Pooled it
- Repeat testing or additional tuberculin skin tests for management of indeterminate results of interferon-gamma release assays: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Role of dormancy survival regulator and resuscitation-promoting factors antigens in differentiating between active and latent tuberculosis: a systematic review and meta-analysis.BMC pulmonary medicine · 2024Pooled it
- Diagnostic performance of biomarkers for differentiating active tuberculosis from latent tuberculosis: a systematic review and Bayesian network meta-analysis.Frontiers in microbiology · 2024Pooled it
- Pooled it
- Pooled it
- Pooled it
- The prevalence of tuberculosis infection in India: A systematic review and meta-analysis.The Indian journal of medical researchPooled it
- Efficacy and Safety of BCG Revaccination WithFrontiers in immunology · 2022Trial
- Tuberculosis in Cirrhosis: A Diagnostic and Therapeutic Challenge.Digestive diseases and sciences · 2026Review
- Upregulation of CREB1 by Mycobacterium Tuberculosis Transcriptionally Activates TREM2 to Promote Macrophage M2 Polarization.Cell biochemistry and function · 2026Article
- Mycobacterium tuberculosis-Specific CFP-10/ESAT-6 CD4 and CD8 T-Cell Non-IFN-γ+ Responses Are Common in Young Kenyan Children Despite Low Reported Tuberculosis Exposure.The Journal of infectious diseases · 2026Article
- Scaling Up Tuberculosis Preventive Treatment: Progress and Factors Influencing Optimization - China, 2022-2025.China CDC weekly · 2026Article
- Immunoinformatic Design and Evaluation of a Multi-Epitope mRNA Vaccine RP14914P Targeting Latent Tuberculosis Infection.Pathogens (Basel, Switzerland) · 2026Article
- Single-cell and spatial profiling highlights TB-induced myofibroblasts as drivers of lung pathology.The Journal of experimental medicine · 2026Article
- Detection for New Biomarkers of Tuberculosis Infection Activity Using Machine Learning Methods.Diseases (Basel, Switzerland) · 2026Review
- Early Mycobacterial Antigens in the Immunodiagnosis of Latent Tuberculosis Infection.Pathogens (Basel, Switzerland) · 2026Review
- Evaluation of diagnostic agreement between STANDARD E TB-Feron ELISA and TB-Feron FIA for tuberculosis infection in prison settings in Paraguay.Frontiers in public health · 2026Article
- Diagnostic efficacy of the TSPOT assay for tuberculosis infection and drug resistance in mycobacterium tuberculosis in patients with malignant tumors.American journal of cancer research · 2026Article
- Exploration of common immune mechanisms and hub genes in latent and active tuberculosis infection.Frontiers in cellular and infection microbiology · 2026Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Latent tuberculosis infection (LTBI) is a subclinical mycobacterial infection defined on the basis of cellular immune response to mycobacterial antigens. The tuberculin skin test (TST) and the interferon gamma release assay (IGRA) are currently used to establish the diagnosis of LTB. However, neither TST nor IGRA is useful to discriminate between active and latent tuberculosis. Moreover, these tests cannot be used to predict whether an individual with LTBI will develop active tuberculosis (TB) or whether therapy for LTBI could be effective to decrease the risk of developing active TB. Therefore, in this article, we review current approaches and some efforts to identify an immunological marker that could be useful in distinguishing LTBI from TB and in evaluating the effectiveness of treatment of LTB on the risk of progression to active TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.